Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon laser photocoagulation versus intravitreal ranibizumab (Lucentis®) injection versus a combination of both.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion

NCT01028248

Central Retinal Vein Occlusion

COMPLETED PHASE1

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

NCT01471691

Branch Retinal Vein Occlusion Central Retinal Vein Occlusion Macular Edema

COMPLETED PHASE1/PHASE2

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)

NCT00486018

Macular Edema Retinal Vein Occlusion

COMPLETED PHASE3

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355

Macular Edema Retinal Vein Occlusion

COMPLETED PHASE1/PHASE2

Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion

NCT02169648

Macular Edema Branch Retinal Vein Occlusion Central Retinal Vein Occlusion

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Edema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

laser photocoagulation to the retina at the area of edema

Group Type ACTIVE_COMPARATOR

Laser photocoagulation

Intervention Type PROCEDURE

laser photocoagulation to the retina at the area of edema

2

intravitreal injection of ranibizumab

Group Type EXPERIMENTAL

Ranibizumab

Intervention Type DRUG

intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8

Laser photocoagulation

Intervention Type PROCEDURE

laser photocoagulation to the retina at the area of edema

3

laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab

Group Type EXPERIMENTAL

Ranibizumab

Intervention Type DRUG

intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ranibizumab

intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8

Intervention Type DRUG

Laser photocoagulation

laser photocoagulation to the retina at the area of edema

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lucentis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged 18 years and older with chronic (\> 3months, \< 18 months) macular edema secondary to branch retinal vein occlusion
* Patients who at baseline have a BSCVA in the study eye between 20/320 and equivalent to 20/40, using an ETDRS chart measured at 4 meters
* Patients who at baseline have a chronic macular edema (\> 3 months) in the study eye with the following characteristics as determined by fluorescein angiography:
* Evidence that the macular edema extends under the geometric center of the foveal avascular zone.
* Evidence that the edema is only secondary to BRVO (no other relevant ocular diseases, e.g. uveitis).
* Patients who at baseline have a chronic macular edema (\> 3 months) in the study eye with the following characteristics as determined by optical coherence tomography (OCT 3):
* Evidence that central macular thickness is \> 225 μm.
* Ability of subject to understand character and individual consequences of clinical trial.
* Signed and dated informed consent of the subject must be available before start of any specific trial procedures.
* For women with childbearing potential, adequate contraception (negative pregnancy test result, serum or urine at trial entry, after treatment and at end of study).
* Only one eye of a patient may be included to this trial.

Exclusion Criteria

* Patients who at baseline
* Have a relevant ocular disease which may be associated with increased intraocular VEGF levels (namely uveitis, neovascular glaucoma, neovascular age-related macular degeneration, diabetic retinopathy, diabetic maculopathy, ocular ischemic syndrome, and others)
* Have a relevant systemic disease which may be associated with increased systemic VEGF levels (namely all malignancies)
* Had previous treatment for macular edema (laser, triamcinolone, vitrectomy)
* Pregnancy and lactation.
* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.
* Participation in other clinical trials within the last 3 months.
* Medical or psychological condition that would not permit completion of the trial or signing of informed consent.
* Arterial hypertension refractory to medical treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No